M. Araki, T. Matsuoka, K. Miyamoto, S. Kusunoki, M. Murata, T. Yamamura. Tocilizumab as an invaluable disease-modifying drug in neuromyelitis optica. MULTIPLE SCLEROSIS JOURNAL. 2015. 21. 74-75
T. Matsuoka, A. Chiba, T. Aranami, M. Nakamura, W. Sato, S. Miyake, T. Yamamura. The increase of CD56 high NK cells and activated Treg-cells in patient with neuromyelitis optica after treatment with anti-IL-6R antibody tocilizumab. MULTIPLE SCLEROSIS JOURNAL. 2014. 20. 347-347
The efficacy of tocilizumab in neuromyelitis optica is associated with alterations of regulatory cells and innate lymphocytes.
(8th Annual Neuromyelitis Optica Roundtable Conference. 2016)